EUVIMEDEUVIMED entdecken
Crossref

Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab

Raffaele Raimondi, Tina Felfeli, Anna Bogdanova-Bennet, Deepali Varma, Maged Habib, Ajay Kotagiri, David H Steel, Michael Grinton

Ophthalmology Retina · 2024-06 · 8 (6) · 537-544

DOI: 10.1016/j.oret.2023.11.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmology Retina, 2024-06. Verfasst von Raffaele Raimondi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom. Electronic address: raffor9@gmail.com. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Intravitreal Injections, Visual Acuity. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Roche, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsIntravitreal InjectionsVisual AcuityTomography, Optical CoherenceWet Macular DegenerationAngiogenesis InhibitorsDrug SubstitutionHumansRetrospective StudiesMaleFemaleAgedTreatment OutcomeFollow-Up StudiesAged, 80 and overVascular Endothelial Growth Factor AFluorescein AngiographyFundus OculiMacula Lutea

Stichwörter der Autor:innen

AfliberceptFaricimabNeovascular age-related macular degenerationnAMD

Substanzen

Receptors, Vascular Endothelial Growth FactorafliberceptRecombinant Fusion ProteinsAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom. Electronic address: raffor9@gmail.com.
  • Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; The Institute of Health Policy, Management and Evaluation (IHPME), Dalla Lana School of Public Health, University of Toronto, Toro…
  • Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom.
  • Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom; Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Förderung

  • Roche
  • Bayer

Zitieren

APA

Raimondi, R., Felfeli, T., Bogdanova-Bennet, A., Varma, D., Habib, M., Kotagiri, A., Steel, D. H., & Grinton, M. (2024). Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab. Ophthalmology Retina, 8(6), 537-544. https://doi.org/10.1016/j.oret.2023.11.015

Vancouver

Raimondi R, Felfeli T, Bogdanova-Bennet A, Varma D, Habib M, Kotagiri A, et al. Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab. Ophthalmology Retina. 2024;8(6):537-544. doi:10.1016/j.oret.2023.11.015

BibTeX
@article{Raimondi2024,
  author = {Raimondi, Raffaele and Felfeli, Tina and Bogdanova-Bennet, Anna and Varma, Deepali and Habib, Maged and Kotagiri, Ajay and Steel, David H and Grinton, Michael},
  title = {Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab},
  journal = {Ophthalmology Retina},
  year = {2024},
  volume = {8},
  number = {6},
  pages = {537--544},
  doi = {10.1016/j.oret.2023.11.015}
}
Kostenlos starten →